Nov 13 (Reuters) - Entero Therapeutics Inc :
* ENTERO THERAPEUTICS ANNOUNCES PROPOSED REVERSE MERGER WITH JOURNEY THERAPEUTICS, A CLINICAL STAGE, FIRST-IN-CLASS, NEXT-GENERATION ADC-RIVALLING NANO-IMMUNOCONJUGATES BIOPHARMACEUTICAL COMPANY
* ENTERO THERAPEUTICS INC - JOURNEY SHAREHOLDERS TO ACQUIRE 99% OF ENTERO EQUITY
* ENTERO THERAPEUTICS INC - COMBINED COMPANY TO OPERATE AS JOURNEY THERAPEUTICS AND APPLY FOR NASDAQ LISTING
Source text: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments